Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Allogene Therapeutics (ALLO) Accounts Payables (2019 - 2025)

Historic Accounts Payables for Allogene Therapeutics (ALLO) over the last 7 years, with Q3 2025 value amounting to $3.7 million.

  • Allogene Therapeutics' Accounts Payables fell 3281.87% to $3.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 million, marking a year-over-year decrease of 3281.87%. This contributed to the annual value of $5.4 million for FY2024, which is 852.98% down from last year.
  • Allogene Therapeutics' Accounts Payables amounted to $3.7 million in Q3 2025, which was down 3281.87% from $4.9 million recorded in Q2 2025.
  • Allogene Therapeutics' Accounts Payables' 5-year high stood at $14.9 million during Q1 2021, with a 5-year trough of $3.7 million in Q3 2025.
  • In the last 5 years, Allogene Therapeutics' Accounts Payables had a median value of $9.7 million in 2022 and averaged $9.0 million.
  • Per our database at Business Quant, Allogene Therapeutics' Accounts Payables surged by 10662.59% in 2021 and then plummeted by 6250.0% in 2025.
  • Allogene Therapeutics' Accounts Payables (Quarter) stood at $10.3 million in 2021, then soared by 35.45% to $13.9 million in 2022, then plummeted by 57.54% to $5.9 million in 2023, then decreased by 8.53% to $5.4 million in 2024, then plummeted by 31.42% to $3.7 million in 2025.
  • Its Accounts Payables was $3.7 million in Q3 2025, compared to $4.9 million in Q2 2025 and $5.1 million in Q1 2025.